Sutro Biopharma Statistics
Total Valuation
Sutro Biopharma has a market cap or net worth of $75.77 million. The enterprise value is -$75.87 million.
Important Dates
The last earnings date was Thursday, November 6, 2025, after market close.
| Earnings Date | Nov 6, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Sutro Biopharma has 85.14 million shares outstanding. The number of shares has increased by 17.26% in one year.
| Current Share Class | 85.14M |
| Shares Outstanding | 85.14M |
| Shares Change (YoY) | +17.26% |
| Shares Change (QoQ) | +0.34% |
| Owned by Insiders (%) | 1.67% |
| Owned by Institutions (%) | 42.51% |
| Float | 61.02M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.67 |
| Forward PS | 1.66 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.53
| Current Ratio | 2.53 |
| Quick Ratio | 2.39 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -3.53 |
Financial Efficiency
Return on equity (ROE) is -1,810.01% and return on invested capital (ROIC) is -256.77%.
| Return on Equity (ROE) | -1,810.01% |
| Return on Assets (ROA) | -25.80% |
| Return on Invested Capital (ROIC) | -256.77% |
| Return on Capital Employed (ROCE) | -99.12% |
| Revenue Per Employee | $340,794 |
| Profits Per Employee | -$699,248 |
| Employee Count | 310 |
| Asset Turnover | 0.32 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Sutro Biopharma has paid $2.34 million in taxes.
| Income Tax | 2.34M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -69.20% in the last 52 weeks. The beta is 1.61, so Sutro Biopharma's price volatility has been higher than the market average.
| Beta (5Y) | 1.61 |
| 52-Week Price Change | -69.20% |
| 50-Day Moving Average | 0.93 |
| 200-Day Moving Average | 0.96 |
| Relative Strength Index (RSI) | 45.95 |
| Average Volume (20 Days) | 818,577 |
Short Selling Information
The latest short interest is 3.39 million, so 3.99% of the outstanding shares have been sold short.
| Short Interest | 3.39M |
| Short Previous Month | 2.51M |
| Short % of Shares Out | 3.99% |
| Short % of Float | 5.56% |
| Short Ratio (days to cover) | 2.37 |
Income Statement
In the last 12 months, Sutro Biopharma had revenue of $105.65 million and -$216.77 million in losses. Loss per share was -$2.59.
| Revenue | 105.65M |
| Gross Profit | 144.37M |
| Operating Income | -136.55M |
| Pretax Income | -214.42M |
| Net Income | -216.77M |
| EBITDA | -128.99M |
| EBIT | -136.55M |
| Loss Per Share | -$2.59 |
Full Income StatementBalance Sheet
The company has $167.59 million in cash and $17.66 million in debt, giving a net cash position of $149.93 million or $1.76 per share.
| Cash & Cash Equivalents | 167.59M |
| Total Debt | 17.66M |
| Net Cash | 149.93M |
| Net Cash Per Share | $1.76 |
| Equity (Book Value) | -87.27M |
| Book Value Per Share | -1.03 |
| Working Capital | 110.22M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$222.53 million and capital expenditures -$2.58 million, giving a free cash flow of -$225.11 million.
| Operating Cash Flow | -222.53M |
| Capital Expenditures | -2.58M |
| Free Cash Flow | -225.11M |
| FCF Per Share | -$2.64 |
Full Cash Flow StatementMargins
Gross margin is 136.66%, with operating and profit margins of -129.26% and -205.18%.
| Gross Margin | 136.66% |
| Operating Margin | -129.26% |
| Pretax Margin | -202.96% |
| Profit Margin | -205.18% |
| EBITDA Margin | -122.09% |
| EBIT Margin | -129.26% |
| FCF Margin | n/a |
Dividends & Yields
Sutro Biopharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -17.26% |
| Shareholder Yield | -17.26% |
| Earnings Yield | -292.66% |
| FCF Yield | -303.93% |
Analyst Forecast
The average price target for Sutro Biopharma is $1.97, which is 121.35% higher than the current price. The consensus rating is "Hold".
| Price Target | $1.97 |
| Price Target Difference | 121.35% |
| Analyst Consensus | Hold |
| Analyst Count | 7 |
| Revenue Growth Forecast (5Y) | 0.33% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Sutro Biopharma has an Altman Z-Score of -6.97 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -6.97 |
| Piotroski F-Score | 1 |
